Merck, known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology (ASH) Annual Meeting from Dec. 10-13, 2022, in New Orleans, Louisiana and virtually.

New and updated data for KEYTRUDA, Merck’s anti-PD-1 therapy, as well as from the company’s investigational medicines favezelimab (anti-LAG-3 antibody), zilovertamab vedotin (antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 [ROR1]), and nemtabrutinib (reversible, non-covalent Bruton’s tyrosine kinase [BTK] inhibitor) will be featured in nearly 40 abstracts.

“We are focused on accelerating science that can make a significant impact for patients with blood cancers,” said Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories. “At this year’s ASH meeting, we will share how we are building on our established presence with KEYTRUDA and progressing a broad and growing pipeline of investigational candidates across multiple hematologic malignancies. We look forward to sharing the latest data from our promising portfolio and pipeline that show our commitment to addressing patient needs in a range of blood cancers.”